Symmetric dimethylarginine (SDMA) is a small molecule released when the body breaks down proteins that contain methylated arginine. Much of circulating SDMA is cleared through the kidneys, so blood levels tend to rise as glomerular filtration rate (GFR) falls. This has made SDMA an emerging blood biomarker of kidney function, especially because it appears to be less dependent on muscle mass than creatinine.
In human medicine, however, SDMA is not yet a standard replacement for creatinine, estimated GFR (eGFR), cystatin C, or urine albumin testing. Recent studies support its relationship with kidney function and long-term renal impairment, and newer automated assays may make testing easier, but clinical cutoffs and interpretation are still assay-specific. A high SDMA result should therefore be treated as a clue to reduced renal clearance rather than a stand-alone diagnosis of chronic kidney disease (CKD). The result is most useful when compared with creatinine, eGFR, cystatin C, urine albumin, previous values, and the person’s clinical context.
- SDMA is cleared substantially through the kidneys, so blood levels usually rise as filtration declines.
- SDMA appears less dependent on muscle mass than creatinine, which may be useful when creatinine is difficult to interpret.
- There is no single universally accepted human SDMA cutoff for CKD, and reference intervals depend on the assay and laboratory.
- A high SDMA level does not identify the cause of kidney dysfunction and should be interpreted with eGFR, urine testing, and clinical findings.
- SDMA is promising for earlier or complementary kidney assessment, but it is not yet the main guideline-standard test for diagnosing or staging CKD.
Table of Contents
- What SDMA Is and Why the Kidneys Affect It
- How the SDMA Blood Test Works
- What a High SDMA Level Can Mean
- SDMA and Early Kidney Disease
- SDMA vs. Creatinine, Cystatin C, and eGFR
- Factors That Affect SDMA Interpretation
- What to Do After an Abnormal SDMA Result
What SDMA Is and Why the Kidneys Affect It
SDMA stands for symmetric dimethylarginine. It is one of several methylated arginine compounds produced during normal protein turnover. Protein arginine methyltransferase enzymes add methyl groups to arginine residues within proteins. When those proteins are later broken down, free SDMA enters the circulation.
SDMA is closely related to asymmetric dimethylarginine (ADMA), but the two molecules are not interchangeable. ADMA is best known for directly inhibiting nitric oxide synthase. SDMA has different biological effects and is especially interesting as a renal biomarker because kidney clearance is a major route of elimination.
When GFR declines, the kidneys clear SDMA less efficiently and its blood concentration generally increases. Studies in adults have found strong inverse relationships between SDMA and measured or estimated GFR. In a 2016 comparison against measured iothalamate clearance, SDMA correlated strongly with measured GFR and performed similarly to cystatin C in that small study. More recent population research has continued to link higher SDMA with lower kidney function.
This makes SDMA conceptually similar to creatinine and cystatin C: all three are endogenous substances whose blood concentrations are influenced by filtration. None is a direct picture of kidney tissue. A high value primarily suggests that clearance is lower than expected or that another factor affecting production, distribution, or elimination is present.
SDMA should not be confused with a tubular injury marker such as KIM-1 or NGAL. Injury biomarkers may respond to cellular stress or damage, whereas SDMA is mainly studied as a functional filtration marker. A person can have kidney injury before filtration markers rise, and filtration can also fall for hemodynamic reasons without the same pattern of structural damage.
How the SDMA Blood Test Works
SDMA can be measured in serum or plasma. Research laboratories have commonly used liquid chromatography-tandem mass spectrometry, or LC-MS/MS, because it can separate and quantify small molecules with high specificity. In 2025–2026, investigators reported validation of a fully automated human SDMA immunoassay and establishment of a reference interval using more than 500 adult samples. That development may make SDMA easier to measure on routine clinical chemistry analyzers.
The existence of a new assay does not mean that every hospital or outpatient laboratory routinely offers SDMA. Availability remains much less widespread than creatinine, eGFR, or cystatin C. The method also matters because results may be reported in different units, such as μg/dL, ng/mL, or μmol/L, and a reference interval from one method should not automatically be applied to another.
For this reason, the most important “normal range” is the range printed by the laboratory that performed the test. Human SDMA does not currently have one universally adopted clinical threshold that defines CKD across laboratories. A result should not be interpreted using veterinary cutoffs, which are widely discussed online but were developed for animals and are not valid human reference standards.
The test itself generally requires a routine blood sample. There is no universally required fasting protocol for SDMA alone, but instructions may differ if other tests are ordered at the same time. Because SDMA is usually interpreted as part of a broader kidney assessment, the blood draw may include a renal function panel, cystatin C, or other measurements.
A single SDMA measurement gives a snapshot. Serial measurements can be more informative if the same assay is used, because a rising pattern may support declining renal clearance while a stable value can provide reassurance that there has not been a major change in that marker. Even then, biological and analytical variation must be considered before small changes are labeled meaningful.
What a High SDMA Level Can Mean
The most direct interpretation of a high SDMA result is reduced renal clearance. This can occur in CKD, acute kidney injury (AKI), or other situations in which GFR is temporarily reduced. The SDMA number alone usually cannot distinguish among these causes.
In CKD, filtration declines gradually and persistently. A high SDMA accompanied by a repeatedly low eGFR may support the conclusion that kidney filtration is reduced. CKD diagnosis, however, depends on duration and/or persistent markers of kidney damage. A one-time high SDMA cannot establish that the abnormality has been present for three months.
In AKI, filtration can fall over hours to days. Creatinine and SDMA may rise as clearance worsens, but the timing of biomarker changes is not identical and neither should delay urgent evaluation when AKI is suspected. Falling urine output, dehydration, sepsis, obstruction, medication toxicity, or rapidly rising creatinine can be more immediately actionable than waiting for a specialized SDMA result.
High SDMA can also occur in advanced kidney failure, where accumulation may be substantial because renal elimination is markedly reduced. Dialysis and other aspects of end-stage kidney disease complicate interpretation further, and routine management is based on established clinical and laboratory measures rather than an isolated SDMA concentration.
A high result does not tell whether reduced GFR is caused by diabetes, hypertension, glomerulonephritis, urinary obstruction, vascular disease, inherited kidney disease, medication effects, or another condition. It also does not replace urine albumin testing. Albuminuria provides information about glomerular damage and prognosis that a filtration marker cannot provide.
Recent research has also linked higher SDMA with cardiovascular and vascular abnormalities in CKD. These associations are scientifically important but should not be used to interpret an individual SDMA value as a cardiovascular diagnosis or a direct measure of vascular injury. Reduced kidney function itself strongly affects SDMA, making cause-and-effect relationships difficult to separate.
SDMA and Early Kidney Disease
The interest in SDMA as an “early” kidney marker comes largely from the limitations of creatinine. Serum creatinine may remain within a laboratory reference range despite a meaningful decline in GFR, particularly in people with low muscle mass. Because SDMA production appears less strongly tied to skeletal muscle, it has potential to reveal reduced filtration that is less obvious from creatinine alone.
That potential should be described carefully. “Earlier than creatinine” does not mean SDMA has been proven to be the best early screening test for everyone. Human evidence is still developing, and current CKD guidelines center diagnosis and risk classification on eGFR based on creatinine and/or cystatin C together with urine albumin-creatinine ratio.
A 2025 population-based study followed adults for up to a decade and found that higher baseline SDMA was associated with lower renal function at follow-up and greater odds of kidney dysfunction defined by eGFR below 60 mL/min/1.73 m². This supports SDMA as a potentially useful long-term biomarker, but an association does not establish that routine SDMA screening improves outcomes compared with guideline-standard testing.
Other studies have shown that SDMA rises across CKD severity and correlates with cystatin C and measured GFR. Research in pediatric CKD has also explored SDMA as part of multi-biomarker panels for identifying early disease. Those findings are promising but remain different from having a universally validated diagnostic threshold for adults.
Another limitation is that early kidney disease is not always primarily a filtration problem. A person with diabetic kidney disease or glomerular disease can have persistent albuminuria while eGFR remains above 60. SDMA may still be normal because overall filtration is preserved. In that situation, a urine albumin test can detect clinically important kidney damage that no filtration marker—SDMA included—would necessarily identify.
The best role for SDMA may therefore be complementary. It could be useful when creatinine-based estimates are questionable, when additional evidence of reduced filtration is desired, or when research and future clinical algorithms define how SDMA adds value to creatinine and cystatin C. It should not create false reassurance when standard urine or imaging findings already show kidney disease.
SDMA vs. Creatinine, Cystatin C, and eGFR
Each kidney filtration marker has strengths and limitations.
| Marker | Main advantage | Main limitation |
|---|---|---|
| Creatinine | Cheap, standardized, widely available | Influenced by muscle mass, diet, secretion, and some medicines |
| eGFR from creatinine | Transforms creatinine into a clinically useful filtration estimate | Inherits non-GFR influences on creatinine and is unreliable in rapidly changing AKI |
| Cystatin C | Less dependent on muscle mass; improves eGFR accuracy when combined with creatinine | Can be influenced by corticosteroids, thyroid status, inflammation, and other factors |
| SDMA | Strong relationship with GFR and less apparent dependence on muscle mass | Less standardized clinical use, limited availability, and no universal human cutoff |
Creatinine remains the routine starting point because it is inexpensive, standardized, and already integrated into validated eGFR equations. Modern CKD assessment uses a race-free creatinine equation. When greater accuracy is needed, a combined creatinine-cystatin C eGFR is recommended in many situations because the two markers have different non-GFR determinants.
SDMA has not yet been incorporated into an internationally accepted eGFR equation used in routine adult care. That matters because clinicians generally need an estimate in mL/min/1.73 m² for CKD staging, drug decisions, risk assessment, and referral—not just a concentration of a biomarker.
SDMA may be especially appealing in people with unusual muscle mass, but evidence is not yet strong enough to assume that it is always superior to cystatin C or a combined equation. If creatinine appears unreliable, current practice more commonly adds cystatin C or, when precision is essential, uses measured GFR with an exogenous filtration marker.
Another difference is availability. Creatinine and eGFR are reported almost universally with routine chemistry testing. Cystatin C is increasingly available. Human SDMA is still an emerging laboratory test, and clinicians may have limited experience interpreting it.
Factors That Affect SDMA Interpretation
A biomarker can correlate strongly with GFR and still be influenced by other factors. SDMA is often described as less affected by muscle mass than creatinine, but “less affected” does not mean biologically invariant. Age, metabolism, inflammation, cardiovascular disease, and other illnesses may influence concentrations directly or indirectly through kidney function.
Assay method is a major practical factor. LC-MS/MS and immunoassays may not produce perfectly interchangeable values. Reference intervals must be validated for the method, specimen type, and population. A small difference between two results from different laboratories may represent analytical variation rather than a true change in filtration.
Units are another source of confusion. A value in μmol/L cannot be compared directly with a number in μg/dL without conversion. Online discussions may also mix human and veterinary values. A human laboratory report should always be interpreted using its own unit and reference interval.
Acute illness complicates interpretation. When GFR is changing rapidly, no endogenous filtration marker immediately reflects the new steady state. Creatinine, cystatin C, and SDMA all have kinetic behavior. A person with evolving AKI can therefore have a value that lags behind the true fall in filtration.
Dialysis status, transplant status, fluid shifts, and severe systemic disease can further alter the relationship between a biomarker concentration and native kidney filtration. These clinical settings require specialist interpretation and should not rely on a general-population reference interval alone.
Finally, SDMA does not measure every kidney function. The kidneys regulate potassium, sodium, acid-base balance, phosphorus, water, endocrine signaling, and drug handling. A normal SDMA cannot guarantee that these systems are normal, just as a normal creatinine cannot rule out every form of kidney disease.
What to Do After an Abnormal SDMA Result
The first step is to confirm how the test was measured and what reference interval the laboratory uses. Ask whether the value is slightly above the upper limit or markedly abnormal, what units were used, and whether a prior SDMA result is available from the same method.
The next step is to compare SDMA with established kidney measures. Useful tests commonly include serum creatinine, eGFR, cystatin C when indicated, BUN, potassium, bicarbonate, and urine albumin-creatinine ratio. Urinalysis can identify blood, protein, glucose, or sediment abnormalities that point toward specific kidney processes.
If SDMA is high but creatinine-based eGFR appears normal, clinicians may ask whether creatinine is likely to underestimate impairment because of low muscle mass or another factor. Cystatin C or measured GFR can provide an independent comparison. Conversely, a mildly high SDMA with normal creatinine, cystatin C, urine albumin, and stable clinical status may need repeat testing before it is treated as evidence of disease.
An abnormal result should also be placed on a timeline. CKD requires chronicity, generally shown by abnormalities lasting at least three months. A new high SDMA during vomiting, dehydration, infection, urinary obstruction, or medication-related illness may reflect an acute change that needs prompt evaluation rather than CKD staging.
Clinicians should review blood pressure, diabetes, prescription medicines, over-the-counter NSAIDs, supplements, hydration, and symptoms. Imaging may be needed if obstruction or structural disease is suspected. Referral to nephrology depends on the degree and persistence of reduced kidney function, albuminuria, electrolyte problems, rapid progression, diagnostic uncertainty, and other risk factors.
SDMA is best interpreted as an additional filtration signal. A high value can strengthen concern that kidney clearance is reduced, particularly when creatinine is hard to interpret. But until testing is more standardized and prospective studies define how SDMA should change management, established measures such as eGFR, cystatin C, and urine albumin remain central to human kidney disease diagnosis and monitoring.
References
- First automated immunoassay for symmetric dimethylarginine (SDMA) with reference interval establishment 2026
- Symmetric dimethylarginine as a biomarker of renal impairment after a decade of follow-up 2025
- Impaired vascular function in patients with chronic kidney disease who have elevated symmetric dimethylarginine but not asymmetric dimethylarginine 2025
- Revealing novel biomarkers for diagnosing chronic kidney disease in pediatric patients 2024
- Plasma arginine metabolites in health and chronic kidney disease 2023
- Comparison of symmetric dimethylarginine with creatinine, cystatin C and their eGFR equations as markers of kidney function 2016
Disclaimer
Human SDMA testing is an emerging area and is not interpreted with one universal cutoff across laboratories. An abnormal result should be reviewed with established kidney tests, the laboratory’s assay-specific reference interval, prior results, and clinical context. Seek prompt medical evaluation for sharply worsening kidney function, very low urine output, severe swelling or shortness of breath, confusion, or other signs of acute kidney illness.
